Ciprofloxacin concentrations in bone and muscle after oral dosing
- PMID: 2940971
- PMCID: PMC180403
- DOI: 10.1128/AAC.29.3.405
Ciprofloxacin concentrations in bone and muscle after oral dosing
Abstract
Ciprofloxacin, a quinoline derivative with marked gram-negative and staphylococcal activity, may be a valuable orally administered agent for use against soft-tissue and bone infections. The concentrations of this antibiotic in serum, bone, and muscle samples were determined in patients undergoing orthopedic surgery. A total of 18 patients undergoing hip or knee replacement surgery or osteotomy were randomized to receive single oral doses of ciprofloxacin (500 mg, 750 mg, or 1 g); 10 patients with osteomyelitis were given single doses of 500 or 750 mg. Mean levels in bone of more than 1 microgram/g were achieved with the 750-mg ciprofloxacin doses in patients with osteomyelitis (1.4 +/- 1 microgram/g) or with the 1-g doses in patients without infections (1.6 +/- 0.6 microgram/g). The levels in muscle were significantly higher with each increasing dose level. Orally administered ciprofloxacin (750 mg given every 12 h) should provide adequate concentrations in bones and soft tissues to treat most osteomyelitis and soft-tissue infections.
Similar articles
-
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.Antimicrob Agents Chemother. 1984 Nov;26(5):741-4. doi: 10.1128/AAC.26.5.741. Antimicrob Agents Chemother. 1984. PMID: 6517556 Free PMC article.
-
Tissue distribution of ciprofloxacin following oral and intravenous administration.Infection. 1985 Mar-Apr;13(2):78-81. doi: 10.1007/BF01660419. Infection. 1985. PMID: 3158611
-
Multiple-dose ciprofloxacin kinetics in normal subjects.Clin Pharmacol Ther. 1984 Sep;36(3):384-8. doi: 10.1038/clpt.1984.192. Clin Pharmacol Ther. 1984. PMID: 6467798
-
Overview of clinical experience with ciprofloxacin.Eur J Clin Microbiol. 1986 Apr;5(2):214-9. doi: 10.1007/BF02013993. Eur J Clin Microbiol. 1986. PMID: 3013631 Review.
-
Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.Drugs Aging. 1994 Feb;4(2):145-73. doi: 10.2165/00002512-199404020-00007. Drugs Aging. 1994. PMID: 8186542 Review.
Cited by
-
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003. Drugs. 1988. PMID: 3292209 Review.
-
Penetration of enoxacin into bronchial secretions.Antimicrob Agents Chemother. 1987 May;31(5):748-51. doi: 10.1128/AAC.31.5.748. Antimicrob Agents Chemother. 1987. PMID: 3475036 Free PMC article. Clinical Trial.
-
Pseudomonas aeruginosa prosthetic joint-infection outcomes: Prospective, observational study on 43 patients.Front Med (Lausanne). 2022 Dec 8;9:1039596. doi: 10.3389/fmed.2022.1039596. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36569155 Free PMC article.
-
Management of Acute Hematogenous Infection Following Total Knee Arthroplasty: A Case Series of 11 Patients.Orthop Surg. 2016 Nov;8(4):475-482. doi: 10.1111/os.12297. Orthop Surg. 2016. PMID: 28032700 Free PMC article.
-
Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic Surgery.ACS Pharmacol Transl Sci. 2020 May 25;3(3):444-454. doi: 10.1021/acsptsci.0c00045. eCollection 2020 Jun 12. ACS Pharmacol Transl Sci. 2020. PMID: 32566910 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources